TNGX Q1 2023 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+0.1% YoY

Gross Profit

$4M74.7% margin

Operating Income

-$30M-525.3% margin

Net Income

-$28M-485.7% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

-10.1%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$36M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$404M

Total Liabilities

$177M

Stockholders' Equity

$227M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$6M	+0.1%
Gross Profit	$4M	$5M	-15.3%
Operating Income	-$30M	-$25M	-19.3%
Net Income	-$28M	-$25M	-11.1%